Univariable and multivariable Cox regression analyses of potential predictors for 5-year explantation risks due to diminished pain relief; 395 patients (five Saluda patients excluded)
| Variable | Univariable analysis | Multivariable analysis | ||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (years) | 1.00 | 0.98 to 1.03 | 0.80 | 1.00 | 0.97 to 1.03 | 0.99 |
| Gender | ||||||
| Male | 1* | – | 1 | – | ||
| Female | 1.07 | 0.59 to 1.96 | 0.82 | 1.21 | 0.64 to 2.26 | 0.56 |
| Indication | ||||||
| PSPS2 | 1 | 1 | – | |||
| Other | 0.81 | 0.44 to 1.52 | 0.52 | 0.64 | 0.31 to 1.35 | 0.24 |
| Diabetes | ||||||
| No | 1 | – | 1 | – | ||
| Yes | 1.50 | 0.53 to 4.17 | 0.45 | 1.74 | 0.58 to 5.23 | 0.32 |
| Immunosuppressive treatment | ||||||
| No | 1 | – | 1 | – | ||
| Yes | 2.41 | 0.58 to 9.96 | 0.23 | 2.46 | 0.57 to 10.65 | 0.23 |
| Company | ||||||
| Boston Scientific | 1 | – | 1 | – | ||
| Nevro | 0.98 | 0.38 to 2.53 | 0.97 | 0.81 | 0.30 to 2.17 | 0.68 |
| Medtronic | 1.96 | 0.93 to 4.11 | 0.08 | 2.72 | 1.18 to 6.30 | 0.02 |
| Abbott | 1.79 | 0.70 to 4.6 | 0.23 | 1.56 | 0.31 to 7.83 | 0.59 |
| Rechargeable | ||||||
| No | 1 | – | 1 | – | ||
| Yes | 0.91 | 0.49 to 1.67 | 0.76 | 2.21 | 0.97 to 5.07 | 0.06 |
| DRG stimulation | ||||||
| No | 1 | – | 1 | |||
| Yes | 3.03 | 1.20 to 7.71 | 0.02 | 6.73 | 1.26 to 35.88 | 0.03 |
*Reference category. Significant numbers are in bold.
DRG, dorsal root ganglion; PSPS2, persistent spinal pain syndrome type 2.